Compare · COEP vs RVMD
COEP vs RVMD
Side-by-side comparison of Coeptis Therapeutics Holdings Inc. (COEP) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COEP and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $43.91B, about 430.2x COEP ($102.1M).
- Over the past year, COEP is up 29.6% and RVMD is up 358.6% - RVMD leads by 329.0 points.
- RVMD has been more active in the news (18 items in the past 4 weeks vs 4 for COEP).
- RVMD has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Coeptis Therapeutics Holdings Inc.
- Revolution Medicines Inc.
- Price
- $16.27+0.81%
- $204.98-0.03%
- Market cap
- $102.1M
- $43.91B
- 1M return
- +46.05%
- +0.63%
- 1Y return
- +29.64%
- +358.62%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 4
- 18
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest COEP
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Technology Officer Harris Jeffery Keeslar
- SEC Form S-8 filed by Coeptis Therapeutics Holdings Inc.
- Chief Marketing Officer Schadel Christopher Ryan bought $3,920 worth of shares (1,000 units at $3.92) (SEC Form 4)
- SEC Form 10-Q filed by Coeptis Therapeutics Holdings Inc.
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form POSASR filed by Coeptis Therapeutics Holdings Inc.
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Latest RVMD
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Officer Kelsey Stephen Michael exercised 92,531 shares at a strike of $41.71 and sold $18,724,767 worth of shares (92,531 units at $202.36) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Mancini Anthony exercised 9,363 shares at a strike of $33.62 and sold $3,153,807 worth of shares (15,448 units at $204.16) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 43,890 units (SEC Form 4)
- Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
- SEC Form 144 filed by Revolution Medicines Inc.
- Director Kim Lorence H. sold $3,585,837 worth of shares (17,090 units at $209.82) as part of a pre-agreed trading plan (SEC Form 4)
- Morgan Stanley initiated coverage on Revolution Medicines with a new price target
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer